Number (%) or mean ± SD | ||||
---|---|---|---|---|
All patients | HFEM | CM | p-value | |
Patients | 148 | 52 (35.1) | 96 (64.9) | - |
Age, yrs | 47.6 ± 10.6 | 50.2 ± 9.8 | 46.2 ± 10.9 | 0.030 |
Females | 117 (79.1) | 37 (71.1) | 80 (83.3) | 0.127 |
BMI | 23.6 ± 3.5 | 23.4 ± 2.8 | 23.7 ± 3.9 | 0.737 |
Age at CM onset, yrs | 16.8 ± 7.0 | 16.3 ± 7.3 | 17.0 ± 6.9 | 0.589 |
MMDs/MHDs at baseline | 18.8 ± 6.8 | 11.5 ± 1.7 | 22.7 ± 5.1 | < 0.001 |
NRS score | 8.1 ± 1.1 | 7.9 ± 1.0 | 8.2 ± 1.1 | 0.153 |
Pain quality | ||||
Pulsating | 72 (53.0) | 23 (46.9) | 49 (56.4) | 0.559 |
Pressing/tightening | 38 (27.9) | 15 (30.6) | 23 (26.4) | |
Other | 26 (19.1) | 11 (22.5) | 15 (17.2) | |
Unilateral pain | 86 (58.1) | 31 (59.6) | 55 (57.3) | 0.663 |
Unilateral cranial autonomic symptoms | 61 (44.9) | 22 (44.9) | 39 (44.8) | 0.994 |
Allodynia | 82 (55.4) | 31 (59.6) | 51 (53.1) | 0.558 |
Dopaminergic symptoms | 104 (93.7) | 36 (92.3) | 68 (94.4) | 0.974 |
Monthly analgesic medications | 18.9 ± 12.7 | 12.0 ± 3.3 | 22.5 ± 14.3 | < 0.001 |
MO | 69 (71.9) | - | 69 (71.9) | - |
Duration of MO, yrs | 7.3 ± 14.8 | - | 7.3 ± 14.8 | |
Triptan responders | 91 (61.5) | 37 (71.1) | 54 (56.3) | 0.109 |
Pts using concomitant prophylaxis | 46 (32.2) | |||
Tricyclics | 19 (41.3) | 5 (33.3) | 14 (45.2) | 0.877 |
Anticonvulsants | 20 (43.5) | 6 (40.0) | 14 (45.2) | |
Calcium-channels antagonists | 1 (2.2) | - | 1 (3.2) | |
Serotoninergic antagonists | 12 (26.1) | 6 (40.0) | 6 (19.4) | |
Onabotulinum toxin A | 2 (4.3) | 1 (6.7) | 1 (3.2) | |
Prior treatment failures | 4.3 ± 1.4 | 4.0 ± 1.2 | 4.4 ± 1.5 | 0.099 |
3–4 | 99 (66.9) | 40 (76.9) | 59 (61.5) | 0.084 |
> 4 | 49 (33.1) | 12 (23.1) | 37 (38.5) | |
Onabotulinum toxin A respondersa | 9 (34.6) | 5 (62.5) | 4 (22.2) | 0.122 |
Pts with ≥ 1 comorbidity | 94 (63.5) | 32 (61.5) | 62 (64.6) | 0.850 |
Pts with psychiatric comorbidities | 51 (34.4) | 17 (32.7) | 34 (35.4) | 0.879 |
HIT-6 score | 67.3 ± 5.8 | 65.6 ± 6.8 | 68.3 ± 5.0 | 0.008 |
MIDAS score | 80.3 ± 59.9 | 62.4 ± 42.0 | 90.0 ± 65.8 | 0.023 |
Fremanezumab dosing regimen | ||||
Monthly | 98 (66.2) | 38 (73.1) | 60 (62.5) | - |
Quarterly | 50 (33.8) | 14 (26.9) | 36 (37.5) |